A new trading day began on Monday, with Mineralys Therapeutics Inc (NASDAQ: MLYS) stock price down -6.08% from the previous day of trading, before settling in for the closing price of $14.32. MLYS’s price has ranged from $8.24 to $18.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 13.85%. With a float of $40.60 million, this company’s outstanding shares have now reached $64.88 million.
The firm has a total of 51 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 37.70%, while institutional ownership is 65.21%. The most recent insider transaction that took place on Jun 13 ’25, was worth 165,931. In this transaction Chief Medical Officer of this company sold 11,366 shares at a rate of $14.60, taking the stock ownership to the 101,651 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Officer proposed sale 11,366 for $14.60, making the entire transaction worth $165,931.
Mineralys Therapeutics Inc (MLYS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 13.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.14% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Here are Mineralys Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 26.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.74, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.17 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Analysing the last 5-days average volume posted by the [Mineralys Therapeutics Inc, MLYS], we can find that recorded value of 0.67 million was lower than the volume posted last year of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 6.74%. Additionally, its Average True Range was 0.90.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 51.38%, which indicates a significant increase from 3.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.00% in the past 14 days, which was lower than the 89.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.65, while its 200-day Moving Average is $12.87. Now, the first resistance to watch is $14.18. This is followed by the second major resistance level at $14.91. The third major resistance level sits at $15.34. If the price goes on to break the first support level at $13.02, it is likely to go to the next support level at $12.59. Now, if the price goes above the second support level, the third support stands at $11.86.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
With a market capitalization of 876.61 million, the company has a total of 65,175K Shares Outstanding. Currently, annual sales are 0 K while annual income is -177,810 K. The company’s previous quarter sales were 0 K while its latest quarter income was -42,210 K.
